Safety and Efficacy of Immunization with a Late-Liver-Stage Attenuated Malaria Parasite
Olivia A. C. Lamers, Blandine Franke‐Fayard, Jan Pieter R. Koopman, Geert V.T. Roozen, Jacqueline J. Janse, Séverine Chevalley‐Maurel, Fiona J. A. Geurten, Helena M. de Bes-Roeleveld, Eva Iliopoulou, Emil Colstrup, Els Wessels, Geert-Jan van Gemert, Marga van de Vegte‐Bolmer, Wouter Graumans, Thabitha R Stoter, Benjamin Mordmüller, Emma L. Houlder, Teun Bousema, Rajagopal Murugan, Matthew B. B. McCall, Chris J. Janse, Meta Roestenberg
Abstract
BACKGROUND: malaria parasites is an alternative vaccination strategy that has potential to improve protection. METHODS: parasites per milliliter after bites from GA2-infected mosquitoes (in stage A) and after controlled human malaria infection (in stage B). RESULTS: circumsporozoite protein. CONCLUSIONS: In this small trial, GA2 was associated with a favorable immune induction profile and protective efficacy, findings that warrant further evaluation. (Funded by the Bontius Foundation; ClinicalTrials.gov number, NCT04577066.).